|
 Positive data from different trials for advanced gastric, colorectal
and lung cancers presented at the virtual American Society of
Clinical Oncology (ASCO) conference this week showed Enhertu's
effectiveness in patients with mutations in the HER2 gene,
AstraZeneca said on Friday.
Response rate, or the number of patients that experience a reduction
in cancer cells, was 42.9% for Enhertu in patients with
HER2-positive metastatic gastric cancer who had taken two or more
prior treatments, compared to 12.5% with standard regimens.
The drug also cut the risk of death by 41% in these patients, data
from the "DESTINY-Gastric01" trial showed.
Drugmakers are increasingly using biomarker-driven drugs to treat
patients with rare tumours, and AstraZeneca made a $7-billion bet on
the treatment when it partnered with Japan's Daiichi last year to
work on the drug in a direct challenge to Roche.
[to top of second column] |
The breast cancer drug was also successful in reducing the size of tumours by
45.3% in patients with HER2-positive advanced colorectal cancer who had tried at
least two prior therapies, latest data from another trial showed.
Though Enhertu targets the HER2 protein typical of certain breast cancers, the
new data underscores its potential for expanded use and may add to AstraZeneca's
sales, albeit in smaller numbers for a niche market.
The treatment, approved only late last year, brought in $14 million in sales for
the British drugmaker in the first quarter.
Enhertu also helped reduce the size of tumours in 61.9% patients in a study in
patients with a type of rare lung cancer that had relapsed and spread beyond the
lungs.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Maju Samuel)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
